Fast Five Quiz: Chronic Myelogenous Leukemia Management

Emmanuel C. Besa, MD


September 21, 2022

Preferred treatment options for patients with accelerated phase CML include second- or third-generation TKIs (bosutinib, dasatinib, nilotinib, or ponatinib). The first-generation TKI, imatinib, or the protein synthesis inhibitor, omacetaxine, may be considered for patients in whom a second- or third-generation TKI is contraindicated or resisted.

Learn more about medications used in the management of CML.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.